GET THE APP

Thinking beyond QbD: Accelerating risk smart development and tech | 44060
Journal of Pharmaceutical Care & Health Systems

Journal of Pharmaceutical Care & Health Systems
Open Access

ISSN: 2376-0419

Thinking beyond QbD: Accelerating risk smart development & technology transfer


11th World Congress on Pharmaceutical sciences

September 28-29, 2018 | Montreal, Canada

Kishor K Chakraborty

Julphar, Saudi Arabia

Keynote: J Pharma Care Health Sys

Abstract :

A risk-smart QbD-based methodology driven by improved Informatics goes beyond tactical & reactive development and streamlining standards-based Technology Transfer by capturing mechanistic understanding to support the probabilistic modeling approach from early ideation through research, development, optimization, and scale-up as well as integrating standards (ISA-88 and ISA-95) and structuring data in a fully searchable format. Moreover, the recognition of lean QbD risk assessment through process knowledge is a product lifecycle issue as opposed to a once and done aspect of development is a good first step. That recognition shall catalyze organizational development whose ultimate goal is a broad organizational understanding and competence in QbD concepts and tools, focusing on top-down approach of technology transfer beyond Product Development to include Operations, Engineering, QA, Regulatory Affairs and even Finance. A DIbD (Data-integratingbased- design) supported QbD strategy that expands Research, Development and Manufacturing enables seamless information from across the organization to support continuous product and process improvement. It offers significant opportunities to accelerates products to market, reduces compliance costs and improves product quality by reducing the number of experiment cycles, speeding individual cycles and facilitating technology transfer between cycles. Consistency and standards driven through informatics enable rapid technology transfer between scientists and systems, while Cloud-based software deployments enable remote organizations to collaborate in the QbD process.

Biography :

Kishor K Chakraborty is a professional (M Pharm. PhD, MBA) having more than 30 years of diverse global exposure in various research and development assignments with Lederle (a division of American Cyanamid company), Hindustan Antibiotics, Concept Pharma (a farmer subsidiary of Lupin Pharma), Riyadhpharma and currently has been serving as Head – R&D in Julphar Saudi (A leading pharmaceutical company in GCC). He has published & delivered over 20 manuscripts and lectures respectively.

Top